Cheaper Cancer Medicines: What the New Margin Cap Means for Patients

India has brought 137 non-scheduled anti-cancer medicines under trade margin rationalisation. The National Pharmaceutical Pricing Authority, or NPPA, ordered that the trade margin within each medicine’s maximum retail price cannot exceed 30%. The measure responds to concerns about large gaps between procurement prices and MRPs, including in hospital and retail pharmacies.

The new MRP for each medicine is worked out from its average Price to Stockist or distributor price in March 2026. The rule applies across doses and forms, including pills, injections, and combination products. It also covers patented medicines, which were previously outside this particular intervention.

The revised prices take effect on November 9, 2026. By November 4, 70 companies had reported revised MRPs for 120 medicines. Reported reductions averaged 20% to 70%, with the largest reduction reaching 96.45%. Patients can check revised prices through NPPA’s website and the Pharma Sahi Daam app.

A medicine’s maximum retail price, or MRP, is the highest price a patient can be charged for that product before GST is added. The trade margin is the difference between what the manufacturer charges the distributor and the amount built into the patient-facing price for the supply chain. It covers the markup between those stages.

The new rule says that this margin cannot be more than 30% of the MRP. For example, if the distributor price is Rs. 100, an MRP of about Rs. 142.86 would leave Rs. 42.86 as the margin, exactly 30% of that MRP. The order bases calculations on the average distributor price in March 2026.

This limits excessive markups without removing the supply chain. Companies must recalculate MRPs, and pharmacies or hospitals must use the revised maximum price. GST remains additional, so the final bill can be higher than the printed price excluding GST. Patients can verify prices through NPPA tools.

The order covers 137 non-scheduled anti-cancer medicines, including patented products. The medicines may be sold in different doses, forms, or combinations. By November 4, 2026, 70 companies had submitted revised MRPs for 120 of those medicines, showing that implementation was already underway before the November 9 start date.

The government estimates savings of Rs. 3,357.49 crore from the reported MRP reductions. This estimate compares original and revised prices and applies the difference to the volume sold between April 2025 and March 2026. It is therefore based on observed sales volumes, rather than a promise that every patient will save the same amount.

Reported MRP reductions averaged between 20% and 70%. The highest reduction reported was 96.45%. The figures indicate substantial potential relief for patients, but the realised saving for an individual will depend on the medicine used, its previous price, and the quantity required. Prices can be checked through NPPA and Pharma Sahi Daam.

When the rules take effect on November 9, 2026, covered medicines should carry the new maximum retail prices calculated under the 30% trade-margin cap. The change is designed to reduce excessive markups across retail and hospital pharmacies, making the patient-facing price lower in many cases.

The reported figures show the possible scale. Companies had reported average MRP reductions of 20% to 70%, and the highest reported reduction was 96.45%. A patient buying a covered medicine after the effective date should therefore see a lower medicine charge where the company has reduced its MRP. The exact saving will vary by product and quantity.

Pharmacies and hospitals cannot charge above the revised MRP for covered products, although GST is added on top. Companies must use their March 2026 average distributor prices for the calculation. Patients can compare prices using NPPA’s website or the official Pharma Sahi Daam app.

Scheduled medicines already have government-fixed ceiling prices because they appear in the First Schedule of the Drugs (Prices Control) Order, 2013, linked to the National List of Essential Medicines. The NLEM 2022 contains 388 medicines, including 63 anti-cancer medicines. Non-scheduled medicines are outside that list and do not receive the same fixed ceiling-price treatment.

Instead, non-scheduled medicines were mainly subject to price monitoring. Under Paragraph 20, a manufacturer could raise MRP by no more than 10% in twelve months. That rule did not directly limit the gap between a distributor’s price and the final MRP. Market data showed high markups and differences between retail and hospital prices.

The government therefore used Paragraph 19’s extraordinary public-interest powers. On an Expert Committee recommendation, NPPA brought 137 non-scheduled anti-cancer medicines, including patented ones, under margin rationalisation. The aim is to address prices beyond the scheduled essential-drug group and make treatment more affordable.

In 2019, the government piloted Trade Margin Rationalisation for 42 non-scheduled anti-cancer medicines. This was important because those medicines were outside the scheduled group with fixed ceiling prices. The pilot tested whether limiting margins along the supply chain could reduce what patients paid.

The article states that the pilot successfully drove down patient costs. That experience provided a policy foundation for expanding the approach. Later market data also showed high markups and gaps between retail and hospital prices, strengthening the case for a wider intervention.

In 2026, the government built on the pilot by invoking Paragraph 19 of the DPCO, 2013, using extraordinary public-interest powers. Following an Expert Committee recommendation, NPPA included 137 non-scheduled anti-cancer medicines, including patented products. The broader order uses a 30% margin cap and bases new MRPs on average distributor prices from March 2026.

The supply chain connects the manufacturer, distributor or stockist, and the pharmacy or hospital that supplies the patient. Each stage can affect the final price. The manufacturer’s charge to the distributor is the starting point, while later markups contribute to the MRP displayed for patients. A wide gap between these prices can make treatment much more expensive.

The order uses the average distributor price from March 2026 as its reference point. It then sets a maximum retail price in which the trade margin cannot exceed 30% of MRP. For instance, if the distributor price is Rs. 100, the allowed margin cannot be more than 30% of the resulting MRP. GST is added separately.

This approach does not remove distributors, pharmacies, or hospitals. It limits the markup retained within the price charged to patients. The policy followed concerns from State authorities, patients, and civil society about procurement-to-MRP gaps. New prices apply from November 9, 2026, and patients can verify them through NPPA tools.